您要查找的是不是：
- NSCLC Iressa 非小细胞肺癌
- Keyword: ZD1839 NSCLC Disease control rates Adverse events. 关键词：ZD1839非小细胞肺癌疾病控制率不良事件。
- Past, Present and Future of Targeted Therapy in NSCLC. 非小细胞肺癌靶向治疗的过去、现状和未来。
- Objective To investigate the role of FHIT,cyclinD1,CDK4 in NSCLC. 目的研究非小细胞肺癌(NSCLC)中脆弱性组氨酸三联体(FHIT)、细胞周期素D1(cyclinD1)、细胞周期蛋白依赖激酶4(CDK4)的表达与NSCLC发生发展的关系。
- Methods A total of 110 caes with advanced NSCLC were enrolled in study. 方法110例晚期NSCLC患者。
- PrDlonged treatment time adversely edict outcome of radiotherapy for NSCLC. 总疗程时间延长将导致NSCLC放疗疗效的降低。
- There were 6,048 NSCLC patients diagnosed in Taipei VGH between 1987 and 1996. 台北荣民总医院自1987年至1996年共有6048位非小细胞肺癌病患。
- We thin k this protocol is safe and effective for resistant NSCLC patients. 结论：表明本方案对耐药性NSCLC仍然有效，可以作为二线方案应用。
- Gefitinib (Iressa, ZD1839), a specific tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR), is a novel molecular-targeting antineoplastic agent. 摘要吉非替尼是一种新型的分子靶向抗癌药物，它选择性抑制表皮生长因子受体酪氨酸激酶而发挥作用。
- This patient is thus an excellent candidate for a platinum-based regimen for his NSCLC. 因此这位NSCLC患者是采用含铂方案治疗的极佳人选。
- STUDY OBJECTIVES: Regional lymph node (LN) involvement affects the prognosis of patients with surgically resected non-small cell lung cancer (NSCLC). 目的：区域淋巴结（LN）情况影响手术切除非小细胞肺癌(NSCLC)患者的预后。
- IVP and MVP are effective and safe chemotherapeutic protocols for the treatment of advanced NSCLC patients. 以长春地辛为主的IVP及MVP方案为治疗晚期非小细胞肺癌较为有效而安全的化疗方
- The positive rate of Bcl 2 protein expression in SCLC was significantly higher than that in NSCLC (P<0.05). Bcl2蛋白阳性表达率在小细胞肺癌显著高于非小细胞肺癌(P<0.;05)。
- Objective To evaluate the efficacy of VDS in NSCLC patients and to observe the side effects of VDS. 目的观察长春地辛(VDS)对NSCLC的疗效和毒副作用VDS。
- The inactive ingredients of IRESSA tablets are: Tablet core: Lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, povidone, sodium lauryl sulfate and magnesium stearate. 闲置的成分易瑞沙片是：平板核心：乳糖一水合物，微晶纤维素， croscarmellose钠，聚维酮，十二烷基硫酸钠和硬脂酸镁。
- Compared with MVP regimen,MNP regimen is a more effective and safer chemotherapy regimen for advanced NSCLC patients. MNP方案为治疗晚期NSCLC较为有效和安全的化疗方案
- Our five-gene signature is closely associated with relapse-free and overall survival among patients with NSCLC. 我们的五个基因标记与非小细胞肺癌患者的无复发及总生存率密切相关。
- Median survival in the patients with SCLC was 3months, with NSCLC was 8. 5 months. SCLC和NSCLC的中位生存期分别为3个月和8.;5个月。
- Method To observe expression of DDH and VEGF in tissue of NSCLC by immunohistochemistry. 方法运用免疫组化方法检测42例NSCLC手术标本中DDH与VEGF的表达。
- The hRAD17 messenger RNA is frequently detected in NSCLC and its expression is correlated with lymph node metastasis. hRAD17基因在肺癌中高表达 ,其阳性表达与淋巴结转移密切相关。
- 今日热词
-
- 深远海浮式风电平台 - deep-sea floating wind power platform
-
- 京雄高速公路 - Beijing-Xiongan expressway
-
- 农业及相关产业增加值 - the added value of agriculture and related industries
